Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML

The therapeutic approach to Chronic Myeloid Leukemia (CML) has changed since the advent of the tyrosine kinase inhibitor (TKI) imatinib, which was then followed by the second generation TKIs dasatinib, nilotinib, and, finally, by ponatinib, a third-generation drug. At present, these therapeutic opti...

Descripción completa

Detalles Bibliográficos
Autores principales: Carofiglio, Francesca, Lopalco, Antonio, Lopedota, Angela, Cutrignelli, Annalisa, Nicolotti, Orazio, Denora, Nunzio, Stefanachi, Angela, Leonetti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352889/
https://www.ncbi.nlm.nih.gov/pubmed/32586039
http://dx.doi.org/10.3390/ijms21124469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352889/
https://www.ncbi.nlm.nih.gov/pubmed/32586039
http://dx.doi.org/10.3390/ijms21124469

Ejemplares similares